Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Anti-PD-1/PD-L1 Therapy in Patients With Solid Tumors
Clinical trial NCT06631079 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06631079
- Sponsor
- NEC Bio B.V
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-07
- Primary completion
- 2026-07-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.